Sanofi and Regeneron Pharmaceuticals recently presented Phase 3 Chronos study results at the late-breaking oral abstract session of the Annual Meeting of the American Academy of Dermatology.
The Chronos study evaluated the drug Dupixent and showed that patients receiving it with topical corticosteroids (TCS) greatly improved their condition as opposed to patients taking TCS alone to deal with uncontrolled moderate-to-severe atopic dermatitis.
"These new results build upon previous positive Phase 3 monotherapy data. In the CHRONOS study, Dupixent used with topical corticosteroids showed significantly greater clearance of skin lesions and overall disease severity compared to topical corticosteroids alone, which are commonly prescribed for moderate-to-severe atopic dermatitis," Dr. Andrew Blauvelt, president of Oregon Medical Research Center and principal investigator of the study, said. "This study provides positive long-term data for Dupixent, which is important given atopic dermatitis is a chronic inflammatory disease. Additionally, the presentation highlights the critical role of IL-4 and IL-13 as drivers of this atopic condition."
Dupixent is under clinical development; the drug has not been evaluated by any U.S. regulatory authorities.
Alerts Sign-up